Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKM-100802 in healthy volunteers
NCT02041715Phase 1Terminated
- Sponsor
- Arbutus Biopharma Corporation
- Start
- Jan 2014
- Primary completion
- Jul 2015
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of TKM-100802 in Ebola virus disease (EVD) (3 arms), sponsored by Arbutus Biopharma Corporation. Primary endpoint: Safety and tolerability of TKM-100802 at 1 month. Started Jan 2014; status: terminated.
02
Drugs
TKM-100802
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02041715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02041715.